Susan Desmond-Hellmann
|
Title(s) | Professor, Medicine |
---|
School | School of Medicine |
---|
Address | |
---|
Phone | -- |
---|
vCard | Download vCard |
---|
|
|
Title(s) | Professor, School of Medicine |
---|
|
---|
|
Biography University of California, San Francisco | Clinical Fellowship | | Internal Medicine | University of California, San Francisco | Residency | | School of Medicine |
Overview Susan Desmond-Hellmann, M.D., M.P.H., was chancellor of the University of California, San Francisco. She assumed the post August 3, 2009 and recently departed in March of 2014.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF is the only campus in the 10-campus UC system devoted exclusively to the health sciences.
At UCSF, Desmond-Hellmann also holds appointment as Arthur and Toni Rembe Rock Distinguished Professor.
Before joining UCSF, she served as president of product development at Genentech, a position she held from March 2004 through April 30, 2009. In this role, she was responsible for Genentech’s pre-clinical and clinical development, process research and development, business development and product portfolio management. She also served as a member of Genentech’s executive committee, beginning in 1996. She joined Genentech in 1995 as a clinical scientist, and she was named chief medical officer in 1996. In 1999, she was named executive vice president of development and product operations. During her time at Genentech, several of the company’s patient therapeutics (Lucentis, Avastin, Herceptin, Tarceva, Rituxan and Xolair) were approved by the U.S. Food and Drug Administration, and the company became the nation’s No. 1 producer of anti-cancer drug treatments.
In November 2009, Forbes magazine named Desmond-Hellmann as one of the world's seven most "powerful innovators," calling her "a hero to legions of cancer patients." The seven were lauded for their curiosity, empathy and leadership.
She completed her clinical training at UCSF and is board-certified in internal medicine and medical oncology. She holds a bachelor of science degree in pre-medicine and a medical degree from the University of Nevada, Reno, and a master’s degree in public health from the University of California, Berkeley.
Prior to joining Genentech, Desmond-Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. While at Bristol-Myers Squibb, she was the project team leader for the cancer-fighting drug Taxol.
Desmond-Hellmann also has served as associate adjunct professor of epidemiology and biostatistics at UCSF. During her tenure at UCSF, she spent two years as visiting faculty at the Uganda Cancer Institute, studying HIV/AIDS and cancer. She also spent two years in private practice as a medical oncologist before returning to clinical research.
In January 2009, Desmond-Hellmann joined the Federal Reserve Bank of San Francisco’s Economic Advisory Council for a three-year term. In July 2008, she was appointed to the California Academy of Sciences board of trustees.
Desmond-Hellmann was named to the Biotech Hall of Fame in 2007 and as the Healthcare Businesswomen’s Association Woman of the Year for 2006. She was listed among Fortune magazine’s “top 50 most powerful women in business” in 2001 and from 2003 to 2008. In 2005 and 2006, the Wall Street Journal listed Desmond-Hellmann as one of its “women to watch.”
From 2005 to 2008, Desmond-Hellmann served a three-year term as a member of the American Association for Cancer Research board of directors, and from 2001 to 2009, she served on the executive committee of the board of directors of the Biotechnology Industry Organization. She served on the corporate board of Affymetrix from 2004-2009.
ORNG Applications Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Predictors of negotiated NIH indirect rates at US institutions. PLoS One. 2015; 10(3):e0121273.
Johnston SC, Desmond-Hellmann S, Hauser S, Vermillion E, Mia N. PMID: 25794011.
View in: PubMed Mentions: 1 Fields:
-
Improving health with partnerships between academia and industry. JAMA Intern Med. 2013 Jun 24; 173(12):1051-2.
Desmond-Hellmann S. PMID: 23609423.
View in: PubMed Mentions: Fields: Translation: Humans
-
Toward precision medicine: a new social contract? Sci Transl Med. 2012 Apr 11; 4(129):129ed3.
Desmond-Hellmann S. PMID: 22496543.
View in: PubMed Mentions: 11 Fields: Translation: Humans
-
Making translation work. Science. 2011 Jun 17; 332(6036):1359.
Williams RS, Desmond-Hellmann S. PMID: 21680815.
View in: PubMed Mentions: 1 Fields: Translation: Humans
-
Enhancing ties between academia and industry to improve health. Nat Med. 2011 Apr; 17(4):434-6.
Johnston SC, Hauser SL, Desmond-Hellmann S. PMID: 21475239.
View in: PubMed Mentions: 1 Fields: Translation: Humans
-
An audience with... Susan Desmond-Hellmann. Interview by... Asher Mullard. Nat Rev Drug Discov. 2011 Mar; 10(3):170.
Desmond-Hellmann S. PMID: 21358729.
View in: PubMed Mentions: 1 Fields: Translation: Humans
-
2010: awards show what translation can accomplish. Sci Transl Med. 2010 Dec 22; 2(63):63ed9.
Desmond-Hellmann S. PMID: 21178131.
View in: PubMed Mentions: Fields:
-
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol. 1995 Aug; 13(8):2056-65.
Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA. PMID: 7543562.
View in: PubMed Mentions: 9 Fields: Translation: HumansCTClinical Trials
-
Single-dose ampicillin/sulbactam versus ceftriaxone as treatment for uncomplicated gonorrhoea in a Ugandan STD clinic population with a high prevalence of PPNG infection. J Trop Med Hyg. 1995 Apr; 98(2):95-100.
Hellmann NS, Nsubuga PS, Baingana-Baingi DJ, Desmond-Hellmann SD, Mbidde EK, Granowitz CB, Sande MA. PMID: 7714943.
View in: PubMed Mentions: 1 Fields: Translation: HumansCellsCTClinical Trials
-
Paclitaxel-induced "recall" soft tissue injury. J Clin Oncol. 1995 Feb; 13(2):531.
Basler GA, Desmond-Hellmann S, Florczyk AP. PMID: 7844614.
View in: PubMed Mentions: Fields: Translation: Humans
-
The value of a clinical definition for epidemic KS in predicting HIV seropositivity in Africa. J Acquir Immune Defic Syndr (1988). 1991; 4(7):647-51.
Desmond-Hellmann SD, Mbidde EK, Kizito A, Hellmann NS, Ziegler JL. PMID: 2051304.
View in: PubMed Mentions:
-
Kaposi's sarcoma: recent developments. AIDS. 1991; 5 Suppl 1:S135-42.
Desmond-Hellmann SD, Katongole-Mbidde E. PMID: 1669910.
View in: PubMed Mentions: 1 Fields: Translation: Humans
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
Year | Publications |
---|
1991 | 2 | 1995 | 3 | 2010 | 1 | 2011 | 3 | 2012 | 1 | 2013 | 1 | 2015 | 1 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|